Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
You may also be interested in...
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.
Privately held Swiss immunology and immuno-oncology specialist Numab Therapeutics has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics, and will use the proceeds to advance its own drug pipeline, its co-founder tells Scrip.
Glenmark has kicked off 2019 with more regional deal-making, sealing an alliance for its investigational rhinitis asset with Yuhan in South Korea. But the outlook for the fixed-dose combination nasal spray also hinges on its US approval.